乳腺癌是最常见的恶性肿瘤之一,严重威胁着女性的生命健康。现有的治疗手段以传统的手术、化疗和放疗为主,副作用明显。光动力疗法因创伤小、高选择性和可重复治疗等优点,近年来在癌症治疗领域备受青睐。基于此,本课题组设计了一种新型的金属有机框架载药平台,用于乳腺癌细胞的消融。该金属有机框架材料PCN-224既可以作为光敏剂,也可以作为抗癌药物的搭载平台,以此设计的纳米载药平台对乳腺癌细胞具有双重杀伤效果。首先,将抗癌药物MMAE装载到PCN-224中确定药物负载量,然后比较载药材料PCN@MMAE与单独PCN-224材料的治疗效果。结果表明,在同样的光照条件下,该载药平台能够显著增强杀伤效果,且无明显的暗毒性,有效发挥了光动力治疗和化疗的协同作用。

Breast cancer is one of the most common malignant tumors and poses a serious threat to women’s life and health. Current treatments mainly focus on surgery, chemotherapy, and radiotherapy and have apparent side effects. In the field of cancer treatment, photodynamic therapy (PDT) has been highly favored in tumor treatment in recent years because of its advantages of low invasiveness, high selectivity, and reproducibility of treatment. In this direction, we designed an innovative drug-loaded platform based on a metal-organic framework (MOF) for the ablation of breast cancer cells. MOF material PCN-224 can be used as a photosensitizer and a platform for carrying anticancer drugs, and the designed drug-loaded nanoplatform has a double killing effect on breast cancer cells. First, we loaded the anticancer drug MMAE into PCN-224 to determine the drug-loading capacity. Furthermore, the therapeutic effects of the drug-carrying material PCN@MMAE and the bare PCN-224 material were compared. Results showed that under identical illumination conditions, the drug-loaded platform significantly enhanced the killing effect without any obvious dark toxicity and effectively exhibited a synergistic effect of photodynamic therapy and chemotherapy.